This five-question survey of oncologists focuses on treatments for metastatic or locally advanced, HR+/HER2- breast cancer. Ibrance (palbociclib; PFE) was granted accelerated approval by the FDA in February 2015, and its label currently includes the patient population also commonly treated with Afinitor (everolimus; NVS). Although Ibrance demonstrated a strong improvement in median progression- free survival (PFS) in the registrational, Phase II PALOMA-1 trial, the drug did not strongly improve overall survival (OS), and patients had a high rate of neutropenia. However, the effect of this drug on OS may be confounded by subsequent treatments received by patients in the placebo arm, and OS was not the primary endpoint for this study.

Other drugs covered in this survey are the following: Halaven (eribulin; Eisai), Abraxane (nab-paclitaxel; CELG), Doxil (pegylated liposomal doxorubicin; JNJ), Gemzar (gemcitabine; LLY), and Xeloda (capecitabine; Roche).

As part of our breast cancer coverage, we are also performing a second pulse focusing on drug/biologic usage and perceptions for the HER2+ breast cancer treatment market.

BioMedTracker will be offering KOL Reports and Physician Pulse Surveys through 2015 for purchase a la carte, or access to all reports and surveys can be purchased as a subscription to KOL Insight. For more information on KOL Insight subscription, please email BioMedTracker or call BioMedTracker Client Services at (858) 200-2357.

To purchase this survey, click the link at the top of the page.

For our disclosures, please read the BioMedTracker Research Standards.